MYDA Advisors LLC Has $3.03 Million Holdings in Benitec Biopharma Limited $BNTC

MYDA Advisors LLC lifted its holdings in shares of Benitec Biopharma Limited (NASDAQ:BNTC) by 221.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 225,000 shares of the biotechnology company’s stock after purchasing an additional 155,000 shares during the period. MYDA Advisors LLC owned 0.66% of Benitec Biopharma worth $3,031,000 as of its most recent filing with the SEC.

A number of other hedge funds also recently modified their holdings of the business. BNP Paribas Financial Markets lifted its holdings in shares of Benitec Biopharma by 44.5% during the third quarter. BNP Paribas Financial Markets now owns 2,937 shares of the biotechnology company’s stock worth $41,000 after purchasing an additional 904 shares during the period. Barclays PLC boosted its position in Benitec Biopharma by 9.1% during the fourth quarter. Barclays PLC now owns 23,211 shares of the biotechnology company’s stock valued at $313,000 after acquiring an additional 1,928 shares during the last quarter. Russell Investments Group Ltd. bought a new stake in Benitec Biopharma during the third quarter valued at $79,000. Bank of America Corp DE grew its holdings in Benitec Biopharma by 2,255.8% during the 2nd quarter. Bank of America Corp DE now owns 6,879 shares of the biotechnology company’s stock worth $80,000 after acquiring an additional 6,587 shares during the period. Finally, JPMorgan Chase & Co. acquired a new stake in Benitec Biopharma during the 2nd quarter worth about $80,000. Institutional investors and hedge funds own 52.19% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on BNTC. Wall Street Zen downgraded Benitec Biopharma from a “hold” rating to a “sell” rating in a report on Saturday. HC Wainwright reiterated a “buy” rating and set a $32.00 price target on shares of Benitec Biopharma in a report on Monday, March 9th. Guggenheim downgraded Benitec Biopharma from a “buy” rating to a “neutral” rating in a report on Wednesday. TD Cowen reiterated a “buy” rating on shares of Benitec Biopharma in a report on Monday, March 9th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Benitec Biopharma in a report on Monday, April 20th. Six investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $27.00.

Benitec Biopharma Stock Performance

Shares of NASDAQ BNTC opened at $11.18 on Monday. The firm’s 50-day moving average price is $11.72 and its 200-day moving average price is $11.84. Benitec Biopharma Limited has a 1-year low of $9.85 and a 1-year high of $17.10. The firm has a market capitalization of $384.03 million, a P/E ratio of -9.81 and a beta of 0.27.

Benitec Biopharma (NASDAQ:BNTC) last announced its quarterly earnings data on Thursday, May 14th. The biotechnology company reported ($0.24) earnings per share for the quarter, beating the consensus estimate of ($0.27) by $0.03. Equities research analysts forecast that Benitec Biopharma Limited will post -1.04 EPS for the current year.

Benitec Biopharma Company Profile

Benitec Biopharma Ltd (NASDAQ: BNTC) is a clinical-stage biotechnology company developing gene-silencing therapies for serious human diseases. The company’s proprietary DNA-directed RNA interference (ddRNAi) platform is designed to enable sustained expression of small RNA molecules that specifically target and silence disease-causing genes. By integrating RNAi sequences directly into DNA constructs, ddRNAi aims to provide a long-term therapeutic effect from a single administration.

Benitec’s lead programs include development of ddRNAi candidates for chronic hepatitis B virus infection and for certain ocular conditions.